keyword
https://read.qxmd.com/read/38349260/calcrl-knockdown-suppresses-cancer-stemness-and-chemoresistance-in-acute-myeloid-leukemia-with-flt3-itd-and-dnm3ta-r882-double-mutations
#21
JOURNAL ARTICLE
Shanhao Tang, Huiling Zhu, Lixia Sheng, Qitian Mu, Yi Wang, Kaihong Xu, Miao Zhou, Zhijuan Xu, An Wu, Guifang Ouyang
Acute myeloid leukemia (AML) patients with FLT3 internal tandem duplication (FLT3-ITD) and DNA methyltransferase 3A (DNMT3A) R882 double mutations had a worse prognosis compared with AML with FLT3-ITD or DNMT3A R882 single mutation. This study was designed to explore the specific role of Calcitonin Receptor Like (CALCRL) in AML with FLT3-ITD and DNMT3A R882 double mutations. MOLM13 cells were transduced with CRISPR knockout sgRNA constructs to establish the FTL3-ITD and DNMT3A-R882 double-mutated AML cell model...
February 2024: Drug Development Research
https://read.qxmd.com/read/38296962/long-noncoding-rna-dleu2-and-ror1-pathway-induces-epithelial-to-mesenchymal-transition-and-cancer-stem-cells-in-breast-cancer
#22
JOURNAL ARTICLE
Syed S Islam, Taher Al-Tweigeri, Layla Al-Harbi, Shafat Ujjahan, Maha Al-Mozaini, Asma Tulbah, Abdelilah Aboussekhra
Breast cancer (BC) patient who receives chemotherapy for an extended length of time may experience profound repercussions in terms of metastases and clinical outcomes due to the involvement of the epithelial-to-mesenchymal transition (EMT) mechanism and enriched cancer stem cells (CSCs). BC cells that express high levels of lncRNA deleted in lymphocytic leukemia-2 (lncRNA DLEU2) and type I tyrosine kinase-like orphan receptor ROR1 (ROR1) may play roles in the enhanced ability of the activation EMT and CSC induction...
January 31, 2024: Cell Death Discovery
https://read.qxmd.com/read/38294636/glycolysis-modulation-by-mettl7b-shapes-acute-lymphoblastic-leukemia-cell-proliferation-and-chemotherapy-response
#23
JOURNAL ARTICLE
Li Zhang, Xiao Liu, Shuai Zhou, Peng Wang, Xuan Zhang
Acute lymphoblastic leukemia (ALL) is a devastating hematological malignancy characterized by uncontrolled proliferation of immature lymphoid cells. While advances in treatment have improved patient outcomes, challenges remain in enhancing therapeutic efficacy and understanding underlying molecular mechanisms. Methyltransferase-like 7B (METTL7B), known for its methyltransferase activity, has been implicated in various solid tumors, yet its role in ALL remains unexplored. Here, we reveal that high METTL7B expression is correlated with poorer prognosis in ALL patients...
January 31, 2024: Human Cell
https://read.qxmd.com/read/38268050/a-novel-aml1-eto-fto-positive-feedback-loop-promotes-leukemogenesis-and-ara-c-resistance-via-stabilizing-igfbp2-in-t-8-21-acute-myeloid-leukemia
#24
JOURNAL ARTICLE
Wei Zhou, Siying Li, Hong Wang, Jingfeng Zhou, Shuyi Li, Guofeng Chen, Wei Guan, Xianli Fu, Clara Nervi, Li Yu, Yonghui Li
BACKGROUND: t(8;21)(q22;q22) is one of the most frequent chromosomal abnormalities in acute myeloid leukemia (AML), leading to the generation of the fusion protein AML1-ETO. Despite t(8;21) AML being considered as a subtype with a favorable prognosis, approximately 30-50% of patients experience drug resistance and subsequent relapse. N6 -methyladenosine (m6 A) is demonstrated to be involved in the development of AML. However, the regulatory mechanisms between AML1-ETO and m6 A-related enzymes and the roles of dysregulated m6 A modifications in the t(8;21)-leukemogenesis and chemoresistance remain elusive...
January 24, 2024: Experimental Hematology & Oncology
https://read.qxmd.com/read/38240344/dna-pkcs-mediated-transcriptional-regulation-of-top2%C3%AE-drives-chemoresistance-in-acute-myeloid-leukemia
#25
JOURNAL ARTICLE
Saket V Mishra, Archisman Banerjee, Debashmita Sarkar, Vishnuvarthan Thangarathnam, Bhausaheb Bagal, Syed K Hasan, Shilpee Dutt
Anthracyclines, topoisomerase 2 enzyme poison that results in DNA damage, are the mainstay of acute myeloid leukemia (AML) treatment. However, acquired resistance to anthracyclines leads to relapse, which currently lacks effective treatment and is the cause of poor survival in AML patients. Therefore, the identification of the mechanisms underlying anthracycline resistance remains an unmet clinical need. Here, using patient-derived primary cultures and clinically relevant cellular models that recapitulate acquired anthracycline resistance in AML, we found GCN5-mediated transcriptional upregulation of DNA-PKcs in AML relapse, independent of the DNA-damage response...
January 19, 2024: Journal of Cell Science
https://read.qxmd.com/read/38223131/clinicopathological-significance-and-expression-pattern-of-bcl2-in-breast-cancer-a-comprehensive-in-silico-and-in-vitro-study
#26
JOURNAL ARTICLE
Shazia Sofi, Umar Mehraj, Nusrat Jan, Abdullah Almilaibary, Irshad Ahmad, Fuzail Ahmad, Manzoor Ahmad Mir
B-cell lymphoma/leukemia gene-2 (Bcl-2) is the primary proto-oncogene that has been shown to work by preventing apoptosis/programmed cell death. Bcl-2 combines a variety of cell-generated signals associated to the survival and death of cells. In glioma, lung, and breast cancer, Bcl-2 over-expression has been linked to an increase in invasion and migration. Many treatment regimens that target Bcl2 have been established and approved, and thus increasing the survival rates of the patients. The primary goal of this research was to recognize new therapeutic compounds that target Bcl2 and assess Bcl2 expression pattern in BC patients...
February 2024: Saudi Journal of Biological Sciences
https://read.qxmd.com/read/38203816/ulk2-is-a-key-pro-autophagy-protein-that-contributes-to-the-high-chemoresistance-and-disease-relapse-in-flt3-mutated-acute-myeloid-leukemia
#27
JOURNAL ARTICLE
Justine Lai, Claire Yang, Chuquan Shang, Will Chen, Michael P Chu, Joseph Brandwein, Raymond Lai, Peng Wang
We recently demonstrated that a small subset of cells in FLT3-mutated acute myeloid leukemia (AML) cell lines exhibit SORE6 reporter activity and cancer stem-like features including chemoresistance. To study why SORE6+ cells are more chemoresistant than SORE6- cells, we hypothesized that these cells carry higher autophagy, a mechanism linked to chemoresistance. We found that cytarabine (Ara-C) induced a substantially higher protein level of LC3B-II in SORE6+ compared to SORE6- cells. Similar observations were made using a fluorescence signal-based autophagy assay...
January 4, 2024: International Journal of Molecular Sciences
https://read.qxmd.com/read/38203669/an-in-vitro-model-for-acute-myeloid-leukemia-relapse-using-the-sore6-reporter
#28
JOURNAL ARTICLE
Justine Lai, Chuquan Shang, Will Chen, Iyare Izevbaye, Michael P Chu, Irwindeep Sandhu, Joseph Brandwein, Raymond Lai, Peng Wang
Many patients diagnosed with acute myeloid leukemia (AML) relapse within two years of the initial remission. The biology of AML relapse is incompletely understood, although cancer stem-like (CSL) cells have been hypothesized to be important. To test this hypothesis, we employed SORE6, a reporter designed to detect the transcriptional activity of the embryonic stem cell proteins Oct4 and Sox2, to identify/purify CSL cells in two FLT3-mutated AML cell lines. Both cell lines contained ~10% of SORE6+ cells in the steady state...
December 29, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/38201437/high-mitochondrial-protein-expression-as-a-potential-predictor-of-relapse-risk-in-acute-myeloid-leukemia-patients-with-the-monocytic-fab-subtypes-m4-and-m5
#29
JOURNAL ARTICLE
Frode Selheim, Elise Aasebø, Øystein Bruserud, Maria Hernandez-Valladares
AML is a highly aggressive and heterogeneous form of hematological cancer. Proteomics-based stratification of patients into more refined subgroups may contribute to a more precise characterization of the patient-derived AML cells. Here, we reanalyzed liquid chromatography-tandem mass spectrometry (LC-MS/MS) generated proteomic and phosphoproteomic data from 26 FAB-M4/M5 patients. The patients achieved complete hematological remission after induction therapy. Twelve of them later developed chemoresistant relapse (RELAPSE), and 14 patients were relapse-free (REL_FREE) long-term survivors...
December 19, 2023: Cancers
https://read.qxmd.com/read/38174649/therapeutic-targeting-in-pediatric-acute-myeloid-leukemia-with-aberrant-hox-meis1-expression
#30
REVIEW
Kristian L Juul-Dam, Neerav N Shukla, Todd M Cooper, Branko Cuglievan, Olaf Heidenreich, E Anders Kolb, Milad Rasouli, Henrik Hasle, C Michel Zwaan
Despite advances in the clinical management of childhood acute myeloid leukemia (AML) during the last decades, outcome remains fatal in approximately one third of patients. Primary chemoresistance, relapse and acute and long-term toxicities to conventional myelosuppressive therapies still constitute significant challenges and emphasize the unmet need for effective targeted therapies. Years of scientific efforts have translated into extensive insights on the heterogeneous spectrum of genetics and oncogenic signaling pathways of AML and identified a subset of patients characterized by upregulation of HOXA and HOXB homeobox genes and myeloid ecotropic virus insertion site 1 (MEIS1)...
December 2023: European Journal of Medical Genetics
https://read.qxmd.com/read/38171389/the-roles-and-mechanisms-of-tgfb1-in-acute-myeloid-leukemia-chemoresistance
#31
JOURNAL ARTICLE
Xue Liang, Ji Zhou, Cong Li, Huiping Wang, Yang Wan, Chun Ling, Lianfang Pu, Wanqiu Zhang, Mengmeng Fan, Jingfang Hong, Zhimin Zhai
Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) patients usually have very poor prognoses, and drug-resistance is one of the major limiting factors. In this study, we aimed to explore the functions of Transforming Growth Factor-β1 (TGFB1) in AML drug-resistance. First, TGFB1 levels in serum and bone marrow are higher in R/R patients compared with newly diagnosed patients, this phenomenon could be due to different sources of secreted TGFB1 according to immunohistochemistry of marrow biopsies...
January 1, 2024: Cellular Signalling
https://read.qxmd.com/read/38069522/differential-co-expression-network-analysis-elucidated-genes-associated-with-sensitivity-to-farnesyltransferase-inhibitor-and-prognosis-of-acute-myeloid-leukemia
#32
JOURNAL ARTICLE
Nurdan Kelesoglu, Medi Kori, Betul Karademir Yilmaz, Ozlem Ates Duru, Kazim Yalcin Arga
Acute myeloid leukemia (AML) is a heterogeneous disease and the most common form of acute leukemia with a poor prognosis. Due to its complexity, the disease requires the identification of biomarkers for reliable prognosis. To identify potential disease genes that regulate patient prognosis, we used differential co-expression network analysis and transcriptomics data from relapsed, refractory, and previously untreated AML patients based on their response to treatment in the present study. In addition, we combined functional genomics and transcriptomics data to identify novel and therapeutically potential systems biomarkers for patients who do or do not respond to treatment...
December 8, 2023: Cancer Medicine
https://read.qxmd.com/read/38052820/deletion-of-mettl3-in-mesenchymal-stem-cells-promotes-acute-myeloid-leukemia-resistance-to-chemotherapy
#33
JOURNAL ARTICLE
Xinai Liao, Danni Cai, Jingru Liu, Haoran Hu, Ruolan You, Zhipeng Pan, Shucheng Chen, Kaiming Xu, Wei Dai, Shuxia Zhang, Xinjian Lin, Huifang Huang
Acute myeloid leukemia (AML) cell survival and chemoresistance are influenced by the existence of bone marrow mesenchymal stem cells (BMMSCs); however, the pathways by which BMMSCs contribute to these processes remain unclear. We earlier revealed that methyltransferase-like 3 (METTL3) expression is significantly reduced in AML BMMSCs and that METTL3 mediates BMMSC adipogenesis to promote chemoresistance in human AML cell lines in vitro. In this investigation, we evaluated the METTL3 function in vivo. Mice exhibiting a conditional removal of Mettl3 in BMMSCs were developed by mating Prrx1-CreERT2 ;Mettl3fl/+ mice with Mettl3fl/fl mice using the CRISPR-Cas9 system...
December 5, 2023: Cell Death & Disease
https://read.qxmd.com/read/38048862/exosome-shuttled-fto-from-bm-mscs-contributes-to-cancer-malignancy-and-chemoresistance-in-acute-myeloid-leukemia-by-inducing-m6a-demethylation-a-nano-based-investigation
#34
JOURNAL ARTICLE
Ruirui Kou, Tian Li, Caizhu Fu, Duanfeng Jiang, Yue Wang, Jie Meng, Ruilan Zhong, Changjiu Liang, Min Dong
Although bone marrow mesenchymal stem cells (BM-MSCs)-derived exosomes have been reported to be closely associated with acute myeloid leukemia (AML) progression and chemo-resistance, but its detailed functions and molecular mechanisms have not been fully delineated. Besides, serum RNA m6A demethylase fat mass and obesity-associated protein (FTO)-containing exosomes are deemed as important indicators for cancer progression, and this study aimed to investigate the role of BM-MSCs-derived FTO-exosomes in regulating the malignant phenotypes of AML cells...
December 2, 2023: Environmental Research
https://read.qxmd.com/read/38045173/cxcr2-inhibition-overcomes-ponatinib-intolerance-by-eradicating-chronic-myeloid-leukemic-stem-cells-through-pi3k-akt-mtor-and-dipeptidylpeptidase-%C3%A2-cd26
#35
JOURNAL ARTICLE
Ji-Hea Kim, Ka-Won Kang, Yong Park, Byung Soo Kim
This study explores the therapeutic potential of targeting CXCR2 in patients afflicted with ponatinib-resistant chronic myeloid leukemia (CML). Ponatinib, a third-generation tyrosine kinase inhibitor (TKI), was initially designed for treating patients with CML harboring the T315I mutation. However, resistance or intolerance issues may lead to treatment discontinuation. Additionally, TKIs have exhibited limitations in eradicating quiescent CML stem cells. Our investigation reveals the activation of CXC chemokine receptor 2 (CXCR2) signaling in response to chemotherapeutic stress...
November 2023: Heliyon
https://read.qxmd.com/read/38043785/unveiling-autophagy-complexity-in-leukemia-the-molecular-landscape-and-possible-interactions-with-apoptosis-and-ferroptosis
#36
JOURNAL ARTICLE
Young Yun Jung, Kwang Seok Ahn, Mingzhi Shen
Autophagy is a self-digestion multistep process in which causes the homeostasis through degradation of macromolecules and damaged organelles. The autophagy-mediated tumor progression regulation has been a critical point in recent years, revealing the function of this process in reduction or acceleration of carcinogenesis. Leukemia is a haematological malignancy in which abnormal expansion of hematopoietic cells occurs. The current and conventional therapies from chemotherapy to cell transplantation have failed to appropriately treat the leukemia patients...
December 1, 2023: Cancer Letters
https://read.qxmd.com/read/38039756/abc-transporters-are-predictors-of-treatment-failure-in-acute-myeloid-leukaemia
#37
JOURNAL ARTICLE
Ela Cerovska, Cyril Salek, David Kundrat, Sarka Sestakova, Adam Pesek, Ivana Brozinova, Monika Belickova, Hana Remesova
INTRODUCTION: To date, no chemoresistance predictors are included in acute myeloid leukaemia (AML) prognostic scoring systems to distinguish responding and refractory AML patients prior to chemotherapy. ABC transporters have been described as altering AML chemosensitivity; however, a relevant study investigating their role at various molecular levels was lacking. METHODS: Gene expression, genetic variants, methylation and activity of ABCA2, ABCA5, ABCB1, ABCB6, ABCC1, ABCC3 and ABCG2 were analysed in AML blasts and healthy myeloblasts...
November 30, 2023: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/37971569/glucose-increases-proliferation-and-chemoresistance-in-chronic-myeloid-leukemia-via-decreasing-antioxidant-properties-of-%C3%AF-3-polyunsaturated-fatty-acids-in-the-presence-of-iron
#38
JOURNAL ARTICLE
Samira Shahraki, Fatemeh Bahraini, Behzad Mesbahzadeh, Mahtab Sayadi, Seyed Mehdi Sajjadi
BACKGROUND: There is a strong association between hyperglycemia, oxidative stress, inflammation and the onset and progression of diabetes which causes a higher risk of cancer. This study investigated, the effect of concomitant use of omega-3 polyunsaturated fatty acids (ω-3 PUFAs) with iron supplements in hyper-glucose conditions on the K-562 cell line. METHODS: The effects of iron, ω-3 PUFAs, and a combination of both on K-562 cells were investigated under normal and high glucose conditions...
November 16, 2023: Molecular Biology Reports
https://read.qxmd.com/read/37948336/dual-targeting-of-mcl-1-and-bcl-2-to-overcome-chemoresistance-in-cervical-and-colon-cancer
#39
JOURNAL ARTICLE
Ling Wang, Changlei Xi, Rong Liu, Tingting Ye, Ning Xiang, Jinfang Deng, Hui Li
After an initial positive response to chemotherapy, cancer patients often become resistant and experience relapse. Our previous research identified eukaryotic translation initiation factor 4E (eIF4E) as a crucial target to overcome chemoresistance. In this study, we delved further into the role and therapeutic potential of myeloid cell leukemia 1 (Mcl-1), an eIF4E-mediated target, in chemoresistance. We showed that the levels of phosphor and total eIF4E, as well as Mcl-1, were elevated in chemoresistant cervical but not colon cancer cells...
November 13, 2023: Anti-cancer Drugs
https://read.qxmd.com/read/37932837/fabrication-of-a-three-dimensional-bone-marrow-niche-like-acute-myeloid-leukemia-disease-model-by-an-automated-and-controlled-process-using-a-robotic-multicellular-bioprinting-system
#40
JOURNAL ARTICLE
Dana M Alhattab, Ioannis Isaioglou, Salwa Alshehri, Zainab N Khan, Hepi H Susapto, Yanyan Li, Yara Marghani, Arwa A Alghuneim, Rubén Díaz-Rúa, Sherin Abdelrahman, Shuroug Al-Bihani, Farid Ahmed, Raed I Felimban, Heba Alkhatabi, Raed Alserihi, Malak Abedalthagafi, AlShaibani AlFadel, Abdalla Awidi, Adeel Gulzar Chaudhary, Jasmeen Merzaban, Charlotte A E Hauser
BACKGROUND: Acute myeloid leukemia (AML) is a hematological malignancy that remains a therapeutic challenge due to the high incidence of disease relapse. To better understand resistance mechanisms and identify novel therapies, robust preclinical models mimicking the bone marrow (BM) microenvironment are needed. This study aimed to achieve an automated fabrication process of a three-dimensional (3D) AML disease model that recapitulates the 3D spatial structure of the BM microenvironment and applies to drug screening and investigational studies...
November 6, 2023: Biomaterials Research
keyword
keyword
53849
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.